Video

Dr. El-Khoueiry Discusses Recent Combination Data in HCC

Anthony El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses recent combination data in hepatocellular carcinoma.

Anthony El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses recent combination data in hepatocellular carcinoma (HCC).

There was a lot of discussion surrounding early trials in HCC during the 2018 International Liver Cancer Association Annual Conference, says El-Khoueiry. This includes some trials looking at combination therapy. Most of these trials are looking at anti—PD-1/PD-L1 agents with either tyrosine kinase inhibitors (TKIs) such as sorafenib (Nexavar) and lenvatinib (Lenvima), or with anti-VEGF agents.

One of the trials presented at the conference was the combination of atezolizumab (Tecentriq) with bevacizumab (Avastin). Although it showed a response rate of 60%, it was in a small number of patients, so El-Khoueiry says that this should be interpreted with caution. Further data is awaited. Nonetheless, there is excitement for the possibility for combinations of anti—PD-1/PD-L1 agents with anti-VEGF or TKIs in general, El-Khoueiry concludes.

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School